Trails Edge Capital Partners, LP
An institutional investment manager in ATLANTA, GA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 2077247.
- Reported value$629.9m
- Positions35
Holdings: 35 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| LB Pharmaceuticals IncLBRX | COM SHS | 50180M108 | 49.4 | 7.8% | 1,523,022 | Added+203,660 | |
| Nurix Therapeutics IncNRIX | COM | 67080M103 | 38.2 | 6.1% | 1,573,220 | Reduced−170,000 | |
| Immunocore Holdings plcIMCR | ADS | 45258D105 | 33.8 | 5.4% | 1,063,234 | Added+380,637 | |
| First Tracks BiotherapeuticsTRAX | ORD SHS | 337185102 | 30.5 | 4.8% | 1,514,000 | New+1,514,000 | |
| 4D Molecular Therapeutics inFDMT | COM | 35104E100 | 29.6 | 4.7% | 2,227,917 | Added+925,000 | |
| Biomarin Pharmaceutical IncBMRN | COM | 09061G101 | 29.3 | 4.7% | 512,000 | New+512,000 | |
| Design Therapeutics IncDSGN | COM | 25056L103 | 29.0 | 4.6% | 2,001,282 | Added+1,149,269 | |
| Xenon Pharmaceuticals IncXENE | COM | 98420N105 | 26.6 | 4.2% | 440,000 | Unchanged | |
| Mirum Pharmaceuticals IncMIRM | COM | 604749101 | 26.1 | 4.2% | 223,312 | Reduced−110,000 | |
| Insmed IncINSM | COM PAR $.01 | 457669307 | 24.6 | 3.9% | 230,331 | New+230,331 | |
| Cytokinetics IncCYTK | COM NEW | 23282W605 | 24.5 | 3.9% | 288,089 | Reduced−11,911 | |
| Syndax Pharmaceuticals IncSNDX | COM | 87164F105 | 24.3 | 3.9% | 1,110,000 | Added+408,179 | |
| Neurogene IncNGNE | COM | 64135M105 | 22.5 | 3.6% | 714,885 | Reduced−67,902 | |
| Kailera Therapeutics IncKLRA | COMMON STOCK | 482931102 | 21.7 | 3.4% | 984,786 | New+984,786 | |
| Revolution Medicines IncRVMD | COM | 76155X100 | 21.7 | 3.4% | 115,750 | Reduced−129,250 | |
| Inhibikase Therapeutics IncIKT | COM NEW | 45719W205 | 18.4 | 2.9% | 9,051,318 | Added+993,973 | |
| Incyte CorpINCY | COM | 45337C102 | 17.6 | 2.8% | 155,000 | New+155,000 | |
| Avalo Therapeutics IncAVTX | COM NEW | 05338F306 | 16.5 | 2.6% | 891,881 | New+891,881 | |
| Moonlake ImmunotherapeuticsMLTX | CLASS A ORD | 61559X104 | 14.6 | 2.3% | 750,000 | New+750,000 | |
| Faeth Therapeutics IncFTH | COM NEW | 81728A207 | 12.9 | 2.0% | 515,335 | Added+390,335 | |
| X4 Pharmaceuticals IncXFOR | COM NEW | 98420X202 | 12.0 | 1.9% | 2,571,478 | Unchanged | |
| Opus Genetics IncIRD | COM | 67577R102 | 11.3 | 1.8% | 2,743,658 | Added+2,243,658 | |
| Sol-Gel Technologies Ltd | SHS NEW | M8694L137 | 10.3 | 1.6% | 139,445 | Added+53,949 | |
| Aura Biosciences IncAURA | COM | 05153U107 | 10.2 | 1.6% | 1,443,333 | New+1,443,333 | |
| Century Therapeutics IncIPSC | COM | 15673T100 | 10.1 | 1.6% | 4,134,969 | Added+1,684,976 | |
| Inventiva SAIVA | ADS | 46124U107 | 10.0 | 1.6% | 2,657,997 | Unchanged | |
| CAMP4 Therapeutics CorpCAMP | COM | 13463J101 | 8.4 | 1.3% | 1,932,937 | Reduced−6,626 | |
| Altimmune IncALT | COM NEW | 02155H200 | 8.1 | 1.3% | 2,660,000 | New+2,660,000 | |
| Minerva Neurosciences IncNERV | COM NEW | 603380205 | 7.9 | 1.3% | 1,419,000 | Unchanged | |
| Promis Neurosciences IncPMN | COM SHS | 74346M505 | 7.3 | 1.2% | 557,103 | Unchanged | |
| Onkure Therapeutics IncOKUR | COM CL A | 68277Q105 | 6.6 | 1.0% | 1,438,456 | New+1,438,456 | |
| Forte Biosciences Inc | COM NEW | 34962G208 | 5.8 | 0.9% | 273,181 | New+273,181 | |
| Research Alliance Corp III | ORD SHS CL A | G75226103 | 5.4 | 0.8% | 500,000 | New+500,000 | |
| VTV Therapeutics IncVTVT | CL A NEW | 918385204 | 3.2 | 0.5% | 85,192 | Reduced−54,386 | |
| Imagenebio IncIMA | COM | 45175G207 | 1.7 | 0.3% | 282,004 | New+282,004 |
Sold out: 5 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Arcus Biosciences IncRCUS | COM | 03969F109 | 0.0 | 0.0% | 0 | Sold out−1,047,935 | |
| Definium Therapeutics IncDFTX | COM SHS | 24477V105 | 0.0 | 0.0% | 0 | Sold out−1,738,110 | |
| Immunovant IncIMVT | COM | 45258J102 | 0.0 | 0.0% | 0 | Sold out−414,054 | |
| Vaxcyte IncPCVX | COM | 92243G108 | 0.0 | 0.0% | 0 | Sold out−662,470 | |
| Xenon Pharmaceuticals IncXENE | COM | 98420N105 | 0.0 | 0.0% | 0 | Put | Sold out−200,000 |
Source: SEC EDGAR, Form 13F-HR, accession 0002077247-26-000004 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.